Abstract B55: The impact of inactivation of p53 and PTEN tumor suppressors on promotion and progression of human non‐small cell lung carcinoma

2009 ◽  
Author(s):  
Tijana Andjelkovic ◽  
Jasna Bankovic ◽  
Vedrana Milinkovic ◽  
Ana Podolski ◽  
Sabera Ruzdijic ◽  
...  
Keyword(s):  
Lung Carcinoma ◽  
Tumor Suppressors ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
The Impact

scholarly journals Functional redundancy of HSPA1, HSPA2 and other HSPA proteins in non-small cell lung carcinoma (NSCLC); an implication for NSCLC treatment

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Damian Robert Sojka ◽  
Agnieszka Gogler-Pigłowska ◽  
Natalia Vydra ◽  
Alexander Jorge Cortez ◽  
Piotr Teodor Filipczak ◽  
...  
Keyword(s):  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Good Prognosis ◽  
Small Cell ◽  
Cell Phenotype ◽  
Small Cell Lung ◽  
Aberrant Expression ◽  
Cell Lung Carcinoma ◽  
Hsp70 Family ◽  
The Impact

Abstract Heat shock proteins (HSPs) are a large group of chaperones considered critical for maintaining cellular proteostasis. Their aberrant expression in tumors can modulate the course of processes defined as hallmarks of cancer. Previously, we showed that both stress-inducible HSPA1 and testis-enriched HSPA2, highly homologous members of the HSPA (HSP70) family, are often overexpressed in non-small cell lung carcinoma (NSCLC). HSPA1 is among the best characterized cancer-related chaperones, while the significance of HSPA2 for cancer remains poorly understood. Previously we found that in primary NSCLC, HSPA1 was associated with good prognosis while HSPA2 correlated with bad prognosis, suggesting possible different roles of these proteins in cancer. Therefore, in this work we investigated the impact of HSPA1 and HSPA2 on NSCLC cell phenotype. We found that neither paralog-selective nor simultaneous knockdown of HSPA1 and HSPA2 gene expression reduced growth and chemoresistance of NSCLC cells. Only blocking of HSPA proteins using pan-HSPA inhibitors, VER-155008 or JG-98, exerted potent anticancer effect on NSCLC cells, albeit the final outcome was cell type-dependent. Pan-HSPA inhibition sensitized NSCLC cells to bortezomib, but not to platinum derivates. Our result suggests the inhibitors of proteasome and HSPAs seem an effective drug combination for pre-clinical development in highly aggressive NSCLC.

Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma.

1998 ◽  
Vol 16 (8) ◽  
pp. 2708-2714 ◽  
Author(s):  
V C Tjan-Heijnen ◽  
B Biesma ◽  
J Festen ◽  
T A Splinter ◽  
A Cox ◽  
...  
Keyword(s):  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Granulocyte Colony Stimulating Factor ◽  
Colony Stimulating Factor ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Wbc Count ◽  
The Impact ◽  
Stimulating Factor

PURPOSE To evaluate the impact of granulocyte colony-stimulating factor (G-CSF) priming on peripheral-blood cell counts during standard-dose chemotherapy. PATIENTS AND METHODS Twelve patients with relapsed small-cell lung carcinoma (SCLC) were treated with two chemotherapy courses. Six patients received G-CSF priming only before the first course (group A) and the other six patients only before the second course (group B). Each patient served as his own control. Patients were treated with cyclophosphamide, epirubicin, and etoposide (CEE), or with vincristine, ifosfamide, mesna, and carboplatin (VIMP) every 4 weeks. G-CSF was administered subcutaneously 5 microg/kg/d for 6 days until 48 hours before the first or second chemotherapy course. RESULTS Priming caused a lowering of the WBC nadir, with a median value of 0.95 x 10(9)/L (P = .004), and of absolute neutrophil nadir, with a median value of 0.48 x 10(9)/L (P = .03). There was a trend for a lower platelet (PLT) nadir after G-CSF priming (P = .09). G-CSF priming resulted in a prolonged duration of WBC count less than 3.0 x 10(9)/L of +4.25 days (P = .04), and of WBC count less than 1.0 x 10(9)/L of +0.50 days (P = .03). The duration of neutropenia less than 0.5 x 10(9)/L seemed longer in primed courses (+3.75 days, P = .18). The duration of PLT counts less than 100 x 10(9)/L was prolonged by 1.5 days (P = .04). Hemoglobin (Hgb) levels were not influenced by G-CSF priming. CONCLUSION G-CSF administration until 48 hours before the next chemotherapy course increases chemotherapy-associated leukocytopenia and thrombocytopenia. This may be of special concern when G-CSF is administered during dose-densified chemotherapy.

scholarly journals EGFR Status Assessment for Better Care of Early Stage Non-Small Cell Lung Carcinoma: What Is Changing in the Daily Practice of Pathologists?

Cells ◽  
2021 ◽  
Vol 10 (8) ◽  
pp. 2157
Author(s):  
Paul Hofman
Keyword(s):  
Lung Carcinoma ◽  
Early Stage ◽  
Small Cell Lung Carcinoma ◽  
Daily Practice ◽  
Small Cell ◽  
Egfr Mutations ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Recent Emergence ◽  
The Impact

The recent emergence of novel neoadjuvant and/or adjuvant therapies for early stage (I-IIIA) non-small cell lung carcinoma (NSCLC), mainly tyrosine kinase inhibitors (TKIs) targeting EGFR mutations and immunotherapy or chemo-immunotherapy, has suddenly required the evaluation of biomarkers predictive of the efficacy of different treatments in these patients. Currently, the choice of one or another of these treatments mainly depends on the results of immunohistochemistry for PD-L1 and of the status of EGFR and ALK. This new development has led to the setup of different analyses for clinical and molecular pathology laboratories, which have had to rapidly integrate a number of new challenges into daily practice and to establish new organization for decision making. This review outlines the impact of the management of biological samples in laboratories and discusses perspectives for pathologists within the framework of EGFR TKIs in early stage NSCLC.

Clinical Features And Outcomes Of Patients With Small Cell Lung Carcinoma; Retrospective Analysis

2015 ◽  
Vol 3 (2) ◽  
pp. 47 ◽  
Author(s):  
Duygu Unalmış ◽  
Zehra Yasar ◽  
Melih Buyuksirin ◽  
Gulru Polat ◽  
Fatma Demirci Ucsular ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Clinical Features ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma
Sign in / Sign up

Export Citation Format

Share Document